WO1998035681A1 - Oxacarbazepine film-coated tablets - Google Patents

Oxacarbazepine film-coated tablets Download PDF

Info

Publication number
WO1998035681A1
WO1998035681A1 PCT/EP1998/000794 EP9800794W WO9835681A1 WO 1998035681 A1 WO1998035681 A1 WO 1998035681A1 EP 9800794 W EP9800794 W EP 9800794W WO 9835681 A1 WO9835681 A1 WO 9835681A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxacarbazepine
particle size
approximately
film
median particle
Prior art date
Application number
PCT/EP1998/000794
Other languages
French (fr)
Inventor
Burkhard Schlütermann
Original Assignee
Novartis Ag
Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4184588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998035681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU66222/98A priority Critical patent/AU738030B2/en
Priority to SK1098-99A priority patent/SK284503B6/en
Priority to HU0000886A priority patent/HU227807B1/en
Priority to DK98908091T priority patent/DK0966287T3/en
Priority to NZ336946A priority patent/NZ336946A/en
Priority to DE69814367T priority patent/DE69814367T2/en
Priority to CA002277791A priority patent/CA2277791C/en
Priority to IL13103998A priority patent/IL131039A/en
Priority to AT98908091T priority patent/ATE239481T1/en
Application filed by Novartis Ag, Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. filed Critical Novartis Ag
Priority to BR9807368-0A priority patent/BR9807368A/en
Priority to EP98908091A priority patent/EP0966287B1/en
Priority to PL334959A priority patent/PL193332B1/en
Priority to JP10535347A priority patent/JP2000511935A/en
Priority to SI9830485T priority patent/SI0966287T1/en
Publication of WO1998035681A1 publication Critical patent/WO1998035681A1/en
Priority to NO19993919A priority patent/NO327486B1/en
Priority to HK00103912A priority patent/HK1024423A1/en
Priority to US10/429,634 priority patent/US7037525B2/en
Priority to US11/582,802 priority patent/US20070036863A1/en
Priority to US11/879,329 priority patent/US20080014269A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines

Definitions

  • the present invention relates to formulations of oxcarbazepine, in particular film-coated tablets and to processes for the production of said formulations.
  • Oxcarbazepine 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide, like " ⁇ Tegretol [(Novartis) carbamazepine: 5H-dibenz[b,f]azepine-5-carboxamide)]
  • the known dosage forms such as tablets and liquid dosage forms, e.g. suspensions, are suitable for ensuring a uniform concentration of active ingredient in the blood, especially in the case of regularly recurring administration over a prolonged period of treatment. Nevertheless, it is always desirable to develop and improve upon existing formulations with respect to, for example bioavailability and compliance.
  • EP 0 646 374 discloses a formulation of oxacarbazepine which is coated with two layers (an inner and outer layer) containing pigments.
  • the outer layer contains Iron Oxide.
  • the double-coated tablet prevents inhomogeneous colouration of the formulation upon storage.
  • the invention provides in one of its aspects a formulation of oxacarbazepine comprising oxacarbazepine, preferably in a finely ground form, having a median particle size of approximately 2 to 12 ⁇ m, perferably 4 to 12 ⁇ m, more preferably 4 to 10 ⁇ m and with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2%.
  • the formulation according to the invention may contain pharmaceutically acceptable excipients commonly used in pharmaceutical formulations, e.g. for oral administration. ln a preferred embodiment according to the invention the formulation may be in the form of a film-coated tablet
  • a tablet core comprising a therapeutically effective dose of the oxacarbazepine, preferably in a finely ground form, having a median particle size of approximately from 2 to 12 ⁇ m, preferably 4 to 12 ⁇ m, more preferably 4 to 10 ⁇ m with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2 %, and further excipients that are suitable for the production of granules; and b) a hydrophilic permeable outer coating.
  • the formulations e.g. film-coated tablets according to the present invention use oxacarbazepine of fine particle size and narrow particle size distribution and as such may be formulated into dosage forms, e.g solid oral dosage forms such as tablets with relative ease. Furthermore, the fine particle size and narrow particle size distribution may also be beneficial in improving the bioavailablity of oxacarbazepine. Still further the formulations meet all customary requirements, such as storage stability and colour stability.
  • the colour stability may be achieved using only a single coating containing pigments rather than requiring a double coating containing pigments. This has the advantage of rendering the process of formulating the dosage forms relatively simple and efficient. Furthermore, for a given dosage size, e.g. 300mg lower amounts of pigment, e.g. Iron oxide (when employed) are required in the coating.
  • the invention provides in another of its aspects a process for the production of a film- coated tablet containing oxacarbazepine comprising the steps of forming the oxacarbazepine, having a median particle size of approximately from, 2 to 12 ⁇ m, preferably 4 to 12 ⁇ m, more preferably 4 to 10 ⁇ m with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2 %, and optionally other excipients into a central core and coating said core with a hydrophilic permeable outer coating.
  • a process for the production of a film-coated tablet containing oxacarbazepine which comprises finely grinding oxacarbazepine to a median particle size of approximately from 2 to 12 ⁇ m, preferably 4 to 12 ⁇ m, more preferably 4 to 10 ⁇ m with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2 % and, with the admixture of excipients that are suitable for granulation processes, forming the oxacarbazepine into granules, compressing the granules to form tablet cores using conventional tabletting processes, and providing the cores with a hydrophilic permeable outer coating.
  • film-coated tablet denotes a perorally administrable, single-dose, solid dosage form that can be produced by compressing oxacarbazepine with conventional tabletting excipients to form a tablet core using conventional tabletting processes and subsequently coating the core.
  • the tablet cores can be produced using conventional granulation methods, for example wet or dry granulation, with optional comminution of the granules and with subsequent compression and coating. Granulation methods are described, for example, in Voigt, loc. ci , pages 156-169.
  • Suitable excipients for the production of granules are, for example pulverulent fillers optionally having flow-conditioning properties, for example talcum, silicon dioxide, for example synthetic amorphous anhydrous silicic acid of the Syloid ® type (Grace), for example SYLOID 244 FP, microcrystalline cellulose, for example of the Avicel ® type (FMC Corp.), for example of the types AVICEL PH101 , 102, 105, RC581 or RC 591 , Emcocel ® type (Mendell Corp.) or Elcema ® type (Degussa); carbohydrates, such as sugars, sugar alcohols, starches or starch derivatives, for example lactose, dextrose, saccharose, glucose, sorbitol, mannitol, xylitol, potato starch, maize starch, rice starch, wheat starch or amylopectin, tricalcium phosphate, calcium hydrogen phosphate or magnesium tris
  • Granules may be produced in a manner known per se, for example using wet granulation methods known for the production of "built-up" granules or "broken-down" granules.
  • Methods for the formation of built-up granules may operate continuously and comprise, for example simultaneously spraying the granulation mass with granulation solution and drying, for example in a drum granulator, in pan granulators, on disc granulators, in a fluidised bed, by spray-drying or spray-solidifying, or operate discontinuously, for example in a fluidised bed, in a batch mixer or in a spray-drying drum.
  • Suitable equipment for the granulation step are planetary mixers, low and high shear mixers, wet granulation equipment including extruders and spheronisers include, for example, apparatus from the companies Loedige, Glatt, Diosna, Fielder, Collette, Aeschbach, Alexanderwerk, Ytron, Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva and Gabler.
  • the granulation mass consists of comminuted, preferably ground, oxacarbazepine and the excipients mentioned above, for example pulverulent fillers, such as microcrystalline cellulose of the AVICEL type.
  • AVICEL PH 102 is especially suitable.
  • the granulation mass may be in the form of a premix or may be obtained by mixing the oxacarbazepine into one or more excipients or mixing the excipients into the oxacarbazepine.
  • the wet granules are preferably dried, for example in the described manner by tray drying or in a fluidised bed.
  • tablet cores are produced using the so-called compacting or dry granulation method in which the active ingredient is compressed with the excipients to form relatively large mouldings, for example slugs or ribbons, which are comminuted by grinding, and the ground material is compressed to form tablet cores.
  • Suitable excipients for the compacting method are preferably those which are suitable for the conventional direct compression methods, for example dry binders, such as starches, for example potato, wheat and maize starch, microcrystalline cellulose, for example commercial products available under the trademarks Avicel ® , Filtrak ® , Heweten ® or Pharmacel ® , highly dispersed silicon dioxide, for example Aerosil ® , mannitol, lactose, and also polyethylene glycol, especially having a molecular weight of from 4000 to 6000, crossiinked polyvinyipyrrolidone (Polyplasdone ® XL or Koliidon ® CL), crosslinked carboxymethylcellulose (Acdisol ® CMC-XL), carboxymethyicellulose [Nymcel ® , for example ZSB-10, (Nyma)], hydroxypropylmethylcellulose, for example the quality HPMC 603, carboxymethyl starch [Explotab ® (Mendell)
  • Compression to form tablet cores may be carried out in conventional tabletting machines, for example EK-0 Korsch eccentric tabletting machines or rotary tabletting machines.
  • the tablet cores may be of various shapes, for example round, oval, oblong, cylindrical etc., and various sizes, depending on the amount of oxacarbazepine.
  • Oxacarbazepine is known. Its manufacture and therapeutic use as an anticonvulsive are described in German Auslegeschrift 2 011 087 which is incorporated herein by reference.
  • a commercially advantageous process for the preparation of that active ingredient is described in European Patent Application No. 0 028 028 which is incorporated herein by reference.
  • Commercially available dosage forms are provided for peroral administration, for example tablets comprising 300 and 600 mg of active ingredient. Those dosage forms are known by the trademark ® Trileptal (Novartis) and have been introduced in a large number of countries, such as Denmark, Finland, Austria and Belgium.
  • the median particle size of the oxacarbazepine is approximately from 2 to 12 ⁇ m, preferably 4 to 12 ⁇ m, more preferably 4 to 10 ⁇ m with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2 %.
  • the median particle size of the oxacarbazepine is approximately from 4 to 12 ⁇ m, typically 6 to 8 ⁇ m with a maximum residue on a 40 ⁇ m sieve of up to 5%, e.g. 2 %.
  • the known particle size analysis methods are suitable for determining the median particle size, for example particle size measurement using light, for example light-scattering methods or turbidimetric methods, sedimentation methods, for example pipette analysis using an Andreassen pipette, sedimentation scales, photosedimentometers or sedimentation in a centrifugal force field, pulse methods, for example using a Coulter counter, or sorting by means of gravitational or centrifugal force.
  • Those methods are described, inter alia, in Voigt, loc. cit, pages 64-79.
  • oxacarbazepine particles e.g. crystals having the desired particle size
  • conventional comminution and de-agglomeration techniques may be used, for example grinding in an air-jet mill or impact mill, a ball mill, vibration mill, mortar mill or pin mill.
  • the hydrophilic permeable outer coating b) comprises a film-forming material that is permeable to water and intestinal juice and that may be swellable, and is soluble or at least to some extent soluble, in those fluids.
  • Water-permeable film-forming materials are, for example, hydrophilic mixtures of polyvinylpyrrolidone or of a copolymer of polyvinylpyrroiidone and polyvinyi acetate with hydroxypropylmethylcellulose, mixtures of shellac with hydroxypropylmethylcellulose, polyvinyl acetate or copolymers thereof with polyvinylpyrrolidone, or mixtures of water- soluble cellulose derivatives, such as hydroxypropylmethylcellulose, and water-insoluble ethylcellulose.
  • the coating compositions may, if desired, be used in admixture with other additional excipients, such as talcum or silicon dioxide, for example synthetic amorphous silicic acid of the Syloid ® type (Grace), for example SYLOID 244 FP, or wetting agents, for example sorbates or plasticisers, for example the afore-mentioned polyethylene glycols.
  • additional excipients such as talcum or silicon dioxide, for example synthetic amorphous silicic acid of the Syloid ® type (Grace), for example SYLOID 244 FP, or wetting agents, for example sorbates or plasticisers, for example the afore-mentioned polyethylene glycols.
  • Elastic, film-like materials are especially hydrophilic, partially etherified cellulose derivatives.
  • Hydrophilic, partially etherified cellulose derivatives are, for example, lower alkyl ethers of cellulose having an average degree of molar substitution (MS) that is higher than one and lower than three and an average degree of polymerisation of approximately from 100 to 5000.
  • MS average degree of molar substitution
  • the degree of substitution is a measure of the substitution of the hydroxy groups by lower alkoxy groups per glucose unit.
  • the average degree of molar substitution (MS) is an averaged value and indicates the number of lower alkoxy groups per glucose unit in the polymer.
  • the average degree of polymerisation (DP) is also an averaged value and indicates the average number of glucose units in the cellulose polymer.
  • Lower alkyl ethers of cellulose are, for example, cellulose derivatives that are substituted at the hydroxymethyl group (primary hydroxy group) of the glucose unit forming the cellulose chains and, where appropriate, at the second and third secondary hydroxy group by C ⁇ -C alkyl groups, especially methyl or ethyl, or by substituted C C 4 alkyl groups, for example 2-hydroxyethyl, 3-hydroxy-n-propyl, carboxymethyl or 2-carboxyethyl.
  • Suitable lower alkyl ethers of cellulose are preferably cellulose derivatives that are substituted at the hydroxymethyl group (primary hydroxy group) of the glucose unit by the mentioned C r C 4 alkyl groups or by substituted C C 4 alkyl groups and at the second and, where appropriate, third secondary hydroxy group by methyl or ethyl groups.
  • Suitable lower alkyl ethers of cellulose are especially methylcellulose, ethylcellulose, methylhydroxyethylcellulose, methylhydroxypropyicellulose, ethylhydroxyethylceliulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose (in salt form, for example in sodium salt form) or methyicarboxymethylcellulose (also in salt form, for example sodium salt form).
  • Preferred lower alkyl ethers of cellulose are ethylcellulose (DP: approximately from 150 to 1000, MS: approximately from 1.2 to 1.8), for example of the Aquacoat ® type (FMC Corp.), hydroxyethylcellulose (DP: approximately from 120 to 1200, MS: approximately from 1.2 to 2.5) and hydroxypropylcellulose (DP: approximately from 200 to 3000, MS: approximately from 1.0 to 3.0).
  • Water-permeable film-forming materials also include cellulose acetate trimellitate (CAT), and methacrylic acid/methacrylate 1 :1 or 1 :2 copolymer, for example EUDRAGIT L and S, for example EUDRAGIT L 12.5 or S 12.5.
  • CAT cellulose acetate trimellitate
  • EUDRAGIT L and S for example EUDRAGIT L 12.5 or S 12.5.
  • the film-forming material may be sprayed on in the form of an aqueous dispersion of redispersible cellulose acetate phthalate - CAP - (Aquateric ® : FMC), of polyvinyl acetate phthalate - PVAP - (Coatehc ® : Colorcon), of hydroxypropylmethylcellulose phthalate - HPMCP - (Aquacoat ® HP 50 or HP 55: Shin-Etsu) or also, especially, of acrylic acid/methacrylic acid copolymer partially esterified by C C 4 alkyl groups.
  • the film-forming materials may comprise additional excipients, such as, for example, plasticisers, for example triethyl citrate, for example Citroflex ® (Pfizer), triacetin, various phthalates, for example diethyi or dibutyl phthalate, mixed mono- or di-glycerides of the Myvacet ® type (Eastman), for example MYVACET 9-40, the polyethylene glycols mentioned hereinbefore, for example having a molecular weight of approximately from 6000 to 8000, and also ethylene oxide/propylene oxide block copoiymers of the Pluronic ® (BASF) or Synperonic ® (ICI) type, pulverulent mould release agents, for example magnesium trisilicate, starch or synthetic amorphous silicic acid of the SYLOID type, for example SYLOID 244 FP.
  • plasticisers for example triethyl citrate, for example Citroflex ® (Pfizer), triacetin
  • the hydrophilic permeable outer coating b) comprises white pigments, for example titanium dioxide pigments, preferably combined with iron oxide pigments.
  • the iron oxide may be ferric or ferrous iron oxide, preferably Fe 2 0 3 optionally in hydrated form.
  • the amounts employed in the coating will depend upon the size of the particular dosage form.
  • the amount of iron oxide employed may be chosen from about 0.1 mg per dosage form, e.g. tablet, to 1.6mg per dosage form, e.g. tablet, more preferably 0.3mg per dosage form, e.g. tablet to 0.9mg per dosage form, e.g. tablet.
  • the tablet cores may be coated with the hydrophilic permeable coating composition in a manner known per se, using conventional coating methods.
  • the coating composition is dissolved or suspended in water in the desired quantity ratio.
  • excipients such as polyethylene glycol
  • the solution or dispersion is sprayed onto the tablet cores together with other excipients, for example talcum or silicon dioxide, for example SYLOID 244 FP, for example using known methods, such as spray-coating in a fluidised bed, for example using the Aeromatic, Glatt, Wurster or Huttlin (ball coater) system, or also in a coating pan in accordance with the methods known by the names Accela Cota or immersion coating.
  • an aqueous dispersion comprising hydroxypropylmethylcellulose (cellulose HPMC) and pigments is sprayed on.
  • cellulose HPMC hydroxypropylmethylcellulose
  • the formulations e.g. film-coated tablets according to the invention are useful for their anticonvulsive action and are useful as monotherapy or as adjunctive therapy in the control, prevention or treatment of seizure, e.g. resulting from the onset of epilepsy, status epilepticus, cerebrovascular disorders, head injury and alcohol withdrawal.
  • oxacarbazepine and the particular formulation to be administered depend upon a number of factors, e.g. the condition to be treated, the desired duration of treatment and the rate of release of the oxacarbazepine.
  • the amount of oxacarbazepine required and the release rate thereof may be determined by in vitro or in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.
  • Preferred regimes include for monotherapy, 150 to 600mg, e.g 300mg twice per day. Doses of from 1200 to 2400mg/day may be tolerated. Preferred regimes for adjunctive therapy include a starting dose of 300 mg/day. Doses from 600 to 2400 mg/day may be tolerated.
  • Titanium Dioxide 0,935 1 ,496 2,431
  • TRILEPTAL TRILEPTAL
  • cellulose HPM 603 binder
  • AVICEL PH 102 bin, filler, disintegration-promoting excipient
  • a mixer preferably in a high-speed mixer (DIOSNA, LOEDIGE, FIELDER, GLATT etc.).
  • DIOSNA high-speed mixer
  • LOEDIGE LOEDIGE
  • FIELDER FIELDER
  • GLATT high-speed mixer
  • the binder cellulose HPM may be dissolved in the granulation liquid, water, beforehand.
  • AVICEL PH 102, AEROSIL 200 (flow conditioner) and polyvinylpyrrolidone PXL (disintegrator) to the dry granules and comminute and mix in a comminuter (FREWITT, QUADRO-COMILL, FITZMILL).
  • FREWITT QUADRO-COMILL, FITZMILL
  • magnesium stearate lubricant
  • STOECKLIN container mixer VRIECO mixer
  • the lubricant may be added directly to the comminuted material.
  • Compress the final mixture to form TRILEPTAL tablets eccentric press, rotary press: KILIAN, KORSCH, FETTE, MANESTY).
  • oxacarbazepine, cellulose HPM 603 and Avicel PH 102 are mixed together in a planetary mixer (Aeschbach). Alcohol is added to this mixture before it is kneaded in a planetary mixer until a desired consistency is achieved. Thereafter the methodology according to Example 1 is followed to provide coated tablets.
  • Example 1 The same methodology as Example 1 is carried out on the formulation to provide coated tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

The invention relates to formulations, e.g. film-coated tablets containing oxacarbazepine and to processes for the production of said formulations. The film-coated tablets have a tablet core comprising a therapeutically effective dose of oxacarbazepine being in a finely ground form having a mean particle size of from 4 to 12 νm (median value), and a hydrophilic permeable outer coating.

Description

Oxacarbazepine Film-Coated Tablets
The present invention relates to formulations of oxcarbazepine, in particular film-coated tablets and to processes for the production of said formulations.
Oxcarbazepine, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide, like "^Tegretol [(Novartis) carbamazepine: 5H-dibenz[b,f]azepine-5-carboxamide)], is an agent of first choice in the treatment of convulsions. The known dosage forms, such as tablets and liquid dosage forms, e.g. suspensions, are suitable for ensuring a uniform concentration of active ingredient in the blood, especially in the case of regularly recurring administration over a prolonged period of treatment. Nevertheless, it is always desirable to develop and improve upon existing formulations with respect to, for example bioavailability and compliance.
EP 0 646 374 discloses a formulation of oxacarbazepine which is coated with two layers (an inner and outer layer) containing pigments. The outer layer contains Iron Oxide. The double-coated tablet prevents inhomogeneous colouration of the formulation upon storage.
Despite the known forms of oxacarbazepine, it is always desirable to provide improved formulations.
We have now found formulations of oxacarbazepine which are easily processed into dosage forms and which may enhance the bioavailability of oxacarbazepine and increase compliance.
Accordingly, the invention provides in one of its aspects a formulation of oxacarbazepine comprising oxacarbazepine, preferably in a finely ground form, having a median particle size of approximately 2 to 12μm, perferably 4 to 12 μm, more preferably 4 to 10 μm and with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2%.
The formulation according to the invention may contain pharmaceutically acceptable excipients commonly used in pharmaceutical formulations, e.g. for oral administration. ln a preferred embodiment according to the invention the formulation may be in the form of a film-coated tablet
which comprises, a) a tablet core comprising a therapeutically effective dose of the oxacarbazepine, preferably in a finely ground form, having a median particle size of approximately from 2 to 12μm, preferably 4 to 12 μm, more preferably 4 to 10 μm with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2 %, and further excipients that are suitable for the production of granules; and b) a hydrophilic permeable outer coating.
The formulations, e.g. film-coated tablets according to the present invention use oxacarbazepine of fine particle size and narrow particle size distribution and as such may be formulated into dosage forms, e.g solid oral dosage forms such as tablets with relative ease. Furthermore, the fine particle size and narrow particle size distribution may also be beneficial in improving the bioavailablity of oxacarbazepine. Still further the formulations meet all customary requirements, such as storage stability and colour stability.
The colour stability may be achieved using only a single coating containing pigments rather than requiring a double coating containing pigments. This has the advantage of rendering the process of formulating the dosage forms relatively simple and efficient. Furthermore, for a given dosage size, e.g. 300mg lower amounts of pigment, e.g. Iron oxide (when employed) are required in the coating.
The invention provides in another of its aspects a process for the production of a film- coated tablet containing oxacarbazepine comprising the steps of forming the oxacarbazepine, having a median particle size of approximately from, 2 to 12 μm, preferably 4 to 12 μm, more preferably 4 to 10 μm with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2 %, and optionally other excipients into a central core and coating said core with a hydrophilic permeable outer coating.
In a preferred aspect of the invention there is provided a process for the production of a film-coated tablet containing oxacarbazepine which comprises finely grinding oxacarbazepine to a median particle size of approximately from 2 to 12 μm, preferably 4 to 12 μm, more preferably 4 to 10 μm with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2 % and, with the admixture of excipients that are suitable for granulation processes, forming the oxacarbazepine into granules, compressing the granules to form tablet cores using conventional tabletting processes, and providing the cores with a hydrophilic permeable outer coating.
Within the scope of the description of the invention, the terms used hereinbefore and hereinafter are defined as follows:
The term "film-coated tablet" denotes a perorally administrable, single-dose, solid dosage form that can be produced by compressing oxacarbazepine with conventional tabletting excipients to form a tablet core using conventional tabletting processes and subsequently coating the core. The tablet cores can be produced using conventional granulation methods, for example wet or dry granulation, with optional comminution of the granules and with subsequent compression and coating. Granulation methods are described, for example, in Voigt, loc. ci , pages 156-169.
Suitable excipients for the production of granules are, for example pulverulent fillers optionally having flow-conditioning properties, for example talcum, silicon dioxide, for example synthetic amorphous anhydrous silicic acid of the Syloid® type (Grace), for example SYLOID 244 FP, microcrystalline cellulose, for example of the Avicel® type (FMC Corp.), for example of the types AVICEL PH101 , 102, 105, RC581 or RC 591 , Emcocel® type (Mendell Corp.) or Elcema® type (Degussa); carbohydrates, such as sugars, sugar alcohols, starches or starch derivatives, for example lactose, dextrose, saccharose, glucose, sorbitol, mannitol, xylitol, potato starch, maize starch, rice starch, wheat starch or amylopectin, tricalcium phosphate, calcium hydrogen phosphate or magnesium trisilicate; binders, such as gelatin, tragacanth, agar, alginic acid, cellulose ethers, for example methylcellulose, carboxymethylcellulose or hydroxypropylmethylcellulose, polyethylene glycols or ethylene oxide homopolymers, especially having a degree of polymerisation of approximately from 2.0 x 103 to 1.0 x 105 and an approximate molecular weight of about from 1.0 x 105 to 5.0 x 106, for example excipients known by the name Polyox® (Union Carbide), polyvinylpyrrolidone or povidones, especially having a mean molecular weight of approximately 1000 and a degree of polymerisation of approximately from 500 to 2500, and also agar or gelatin; surface-active substances, for example anionic surfactants of the alkyl sulfate type, for example sodium, potassium or magnesium n-dodecyl sulfate, n-tetradecyl sulfate, n-hexadecyl sulfate or n-octadecyl sulfate, of the alkyl ether sulfate type, for example sodium, potassium or magnesium n-dodecyloxyethyl sulfate, n-tetradecyloxyethyl sulfate, n-hexadecyloxyethyi sulfate or n-octadecyloxyethyl sulfate, or of the alkanesulfonate type, for example sodium, potassium or magnesium n-dodecanesulfonate, n-tetradecanesulfonate, n-hexadecanesulfonate or n-octadecanesulfonate, or non-ionic surfactants of the fatty acid polyhydroxy alcohol ester type, such as sorbitan monolaurate, monooleate, monostearate or monopalmitate, sorbitan tristearate or trioleate, polyoxyethylene adducts of fatty acid polyhydroxy alcohol esters, such as polyoxyethylene sorbitan monolaurate, monooleate, monostearate, monopalmitate, tristearate or trioleate, polyethylene glycol fatty acid esters, such as polyoxyethyl stearate, polyethylene glycol 400 stearate, polyethylene glycol 2000 stearate, especially ethylene oxide/propylene oxide block polymers of the Pluronics® (BWC) or Synperonic® (ICI) type.
Granules may be produced in a manner known per se, for example using wet granulation methods known for the production of "built-up" granules or "broken-down" granules.
Methods for the formation of built-up granules may operate continuously and comprise, for example simultaneously spraying the granulation mass with granulation solution and drying, for example in a drum granulator, in pan granulators, on disc granulators, in a fluidised bed, by spray-drying or spray-solidifying, or operate discontinuously, for example in a fluidised bed, in a batch mixer or in a spray-drying drum.
Preferred are methods for the production of broken-down granules, which may be carried out discontinuously and in which the granulation mass first forms a wet aggregate with the granulation solution, which aggregate is then comminuted or formed into granules of the desired particle size and the granules then being dried. Suitable equipment for the granulation step are planetary mixers, low and high shear mixers, wet granulation equipment including extruders and spheronisers include, for example, apparatus from the companies Loedige, Glatt, Diosna, Fielder, Collette, Aeschbach, Alexanderwerk, Ytron, Wyss & Probst, Werner & Pfleiderer, HKD, Loser, Fuji, Nica, Caleva and Gabler. The granulation mass consists of comminuted, preferably ground, oxacarbazepine and the excipients mentioned above, for example pulverulent fillers, such as microcrystalline cellulose of the AVICEL type. AVICEL PH 102 is especially suitable. Depending on the method used, the granulation mass may be in the form of a premix or may be obtained by mixing the oxacarbazepine into one or more excipients or mixing the excipients into the oxacarbazepine. The wet granules are preferably dried, for example in the described manner by tray drying or in a fluidised bed.
According to an alternative process variant, tablet cores are produced using the so-called compacting or dry granulation method in which the active ingredient is compressed with the excipients to form relatively large mouldings, for example slugs or ribbons, which are comminuted by grinding, and the ground material is compressed to form tablet cores.
Suitable excipients for the compacting method are preferably those which are suitable for the conventional direct compression methods, for example dry binders, such as starches, for example potato, wheat and maize starch, microcrystalline cellulose, for example commercial products available under the trademarks Avicel®, Filtrak®, Heweten® or Pharmacel®, highly dispersed silicon dioxide, for example Aerosil®, mannitol, lactose, and also polyethylene glycol, especially having a molecular weight of from 4000 to 6000, crossiinked polyvinyipyrrolidone (Polyplasdone® XL or Koliidon® CL), crosslinked carboxymethylcellulose (Acdisol® CMC-XL), carboxymethyicellulose [Nymcel®, for example ZSB-10, (Nyma)], hydroxypropylmethylcellulose, for example the quality HPMC 603, carboxymethyl starch [Explotab® (Mendell) or Primojel® (Scholtens)], microcrystalline cellulose, for example Avicel® PH 102, dicalcium phosphate, for example Emcompress® or talcum. The addition of small amounts of, for example, lubricants, such as magnesium stearate, is also advantageous.
Compression to form tablet cores may be carried out in conventional tabletting machines, for example EK-0 Korsch eccentric tabletting machines or rotary tabletting machines. The tablet cores may be of various shapes, for example round, oval, oblong, cylindrical etc., and various sizes, depending on the amount of oxacarbazepine. Oxacarbazepine is known. Its manufacture and therapeutic use as an anticonvulsive are described in German Auslegeschrift 2 011 087 which is incorporated herein by reference. A commercially advantageous process for the preparation of that active ingredient is described in European Patent Application No. 0 028 028 which is incorporated herein by reference. Commercially available dosage forms are provided for peroral administration, for example tablets comprising 300 and 600 mg of active ingredient. Those dosage forms are known by the trademark ®Trileptal (Novartis) and have been introduced in a large number of countries, such as Denmark, Finland, Austria and Belgium.
The median particle size of the oxacarbazepine is approximately from 2 to 12 μm, preferably 4 to 12 μm, more preferably 4 to 10 μm with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2 %. In a preferred form of process, the median particle size of the oxacarbazepine is approximately from 4 to 12 μm, typically 6 to 8 μm with a maximum residue on a 40 μm sieve of up to 5%, e.g. 2 %.
The known particle size analysis methods are suitable for determining the median particle size, for example particle size measurement using light, for example light-scattering methods or turbidimetric methods, sedimentation methods, for example pipette analysis using an Andreassen pipette, sedimentation scales, photosedimentometers or sedimentation in a centrifugal force field, pulse methods, for example using a Coulter counter, or sorting by means of gravitational or centrifugal force. Those methods are described, inter alia, in Voigt, loc. cit, pages 64-79.
In order to produce oxacarbazepine particles, e.g. crystals having the desired particle size, conventional comminution and de-agglomeration techniques may be used, for example grinding in an air-jet mill or impact mill, a ball mill, vibration mill, mortar mill or pin mill.
The hydrophilic permeable outer coating b) comprises a film-forming material that is permeable to water and intestinal juice and that may be swellable, and is soluble or at least to some extent soluble, in those fluids.
Water-permeable film-forming materials are, for example, hydrophilic mixtures of polyvinylpyrrolidone or of a copolymer of polyvinylpyrroiidone and polyvinyi acetate with hydroxypropylmethylcellulose, mixtures of shellac with hydroxypropylmethylcellulose, polyvinyl acetate or copolymers thereof with polyvinylpyrrolidone, or mixtures of water- soluble cellulose derivatives, such as hydroxypropylmethylcellulose, and water-insoluble ethylcellulose.
The coating compositions may, if desired, be used in admixture with other additional excipients, such as talcum or silicon dioxide, for example synthetic amorphous silicic acid of the Syloid® type (Grace), for example SYLOID 244 FP, or wetting agents, for example sorbates or plasticisers, for example the afore-mentioned polyethylene glycols.
Elastic, film-like materials are especially hydrophilic, partially etherified cellulose derivatives.
Hydrophilic, partially etherified cellulose derivatives are, for example, lower alkyl ethers of cellulose having an average degree of molar substitution (MS) that is higher than one and lower than three and an average degree of polymerisation of approximately from 100 to 5000.
The degree of substitution is a measure of the substitution of the hydroxy groups by lower alkoxy groups per glucose unit. The average degree of molar substitution (MS) is an averaged value and indicates the number of lower alkoxy groups per glucose unit in the polymer.
The average degree of polymerisation (DP) is also an averaged value and indicates the average number of glucose units in the cellulose polymer.
Lower alkyl ethers of cellulose are, for example, cellulose derivatives that are substituted at the hydroxymethyl group (primary hydroxy group) of the glucose unit forming the cellulose chains and, where appropriate, at the second and third secondary hydroxy group by Cι-C alkyl groups, especially methyl or ethyl, or by substituted C C4alkyl groups, for example 2-hydroxyethyl, 3-hydroxy-n-propyl, carboxymethyl or 2-carboxyethyl.
Suitable lower alkyl ethers of cellulose are preferably cellulose derivatives that are substituted at the hydroxymethyl group (primary hydroxy group) of the glucose unit by the mentioned CrC4alkyl groups or by substituted C C4alkyl groups and at the second and, where appropriate, third secondary hydroxy group by methyl or ethyl groups. Suitable lower alkyl ethers of cellulose are especially methylcellulose, ethylcellulose, methylhydroxyethylcellulose, methylhydroxypropyicellulose, ethylhydroxyethylceliulose, hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose (in salt form, for example in sodium salt form) or methyicarboxymethylcellulose (also in salt form, for example sodium salt form).
Preferred lower alkyl ethers of cellulose are ethylcellulose (DP: approximately from 150 to 1000, MS: approximately from 1.2 to 1.8), for example of the Aquacoat® type (FMC Corp.), hydroxyethylcellulose (DP: approximately from 120 to 1200, MS: approximately from 1.2 to 2.5) and hydroxypropylcellulose (DP: approximately from 200 to 3000, MS: approximately from 1.0 to 3.0).
Water-permeable film-forming materials also include cellulose acetate trimellitate (CAT), and methacrylic acid/methacrylate 1 :1 or 1 :2 copolymer, for example EUDRAGIT L and S, for example EUDRAGIT L 12.5 or S 12.5.
The film-forming material may be sprayed on in the form of an aqueous dispersion of redispersible cellulose acetate phthalate - CAP - (Aquateric®: FMC), of polyvinyl acetate phthalate - PVAP - (Coatehc®: Colorcon), of hydroxypropylmethylcellulose phthalate - HPMCP - (Aquacoat® HP 50 or HP 55: Shin-Etsu) or also, especially, of acrylic acid/methacrylic acid copolymer partially esterified by C C4alkyl groups.
Also suitable is an acrylic acid/methacrylic acid 1 :1 copolymer partially esterified by methyl and/or ethyl groups of the type EUDRAGIT L 30 D or water-dispersed EUDRAGIT L 100-55.
The film-forming materials may comprise additional excipients, such as, for example, plasticisers, for example triethyl citrate, for example Citroflex® (Pfizer), triacetin, various phthalates, for example diethyi or dibutyl phthalate, mixed mono- or di-glycerides of the Myvacet® type (Eastman), for example MYVACET 9-40, the polyethylene glycols mentioned hereinbefore, for example having a molecular weight of approximately from 6000 to 8000, and also ethylene oxide/propylene oxide block copoiymers of the Pluronic® (BASF) or Synperonic® (ICI) type, pulverulent mould release agents, for example magnesium trisilicate, starch or synthetic amorphous silicic acid of the SYLOID type, for example SYLOID 244 FP.
The hydrophilic permeable outer coating b) comprises white pigments, for example titanium dioxide pigments, preferably combined with iron oxide pigments. The iron oxide may be ferric or ferrous iron oxide, preferably Fe203 optionally in hydrated form. When iron oxide is employed, the amounts employed in the coating will depend upon the size of the particular dosage form. Preferably, the amount of iron oxide employed may be chosen from about 0.1 mg per dosage form, e.g. tablet, to 1.6mg per dosage form, e.g. tablet, more preferably 0.3mg per dosage form, e.g. tablet to 0.9mg per dosage form, e.g. tablet.
The tablet cores may be coated with the hydrophilic permeable coating composition in a manner known per se, using conventional coating methods.
For example, the coating composition is dissolved or suspended in water in the desired quantity ratio. If desired, excipients, such as polyethylene glycol, are added. The solution or dispersion is sprayed onto the tablet cores together with other excipients, for example talcum or silicon dioxide, for example SYLOID 244 FP, for example using known methods, such as spray-coating in a fluidised bed, for example using the Aeromatic, Glatt, Wurster or Huttlin (ball coater) system, or also in a coating pan in accordance with the methods known by the names Accela Cota or immersion coating.
Preferably, an aqueous dispersion comprising hydroxypropylmethylcellulose (cellulose HPMC) and pigments is sprayed on.
The formulations, e.g. film-coated tablets according to the invention are useful for their anticonvulsive action and are useful as monotherapy or as adjunctive therapy in the control, prevention or treatment of seizure, e.g. resulting from the onset of epilepsy, status epilepticus, cerebrovascular disorders, head injury and alcohol withdrawal.
The exact dose of oxacarbazepine and the particular formulation to be administered depend upon a number of factors, e.g. the condition to be treated, the desired duration of treatment and the rate of release of the oxacarbazepine. For example, the amount of oxacarbazepine required and the release rate thereof may be determined by in vitro or in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect.
Preferred regimes include for monotherapy, 150 to 600mg, e.g 300mg twice per day. Doses of from 1200 to 2400mg/day may be tolerated. Preferred regimes for adjunctive therapy include a starting dose of 300 mg/day. Doses from 600 to 2400 mg/day may be tolerated.
The following Examples illustrate the invention.
Example 1
Formulations
Example 1 (mg) (mg) (mg)
Tablet Core:
Oxcarbazepine 150 300 600
Avicel PH 102 32,8 65,6 131 ,2
Cellulose HPM 603 4,2 8,4 16,8
Polyvinylpyrrolidone 10 20 40
Aerosil 200 0,8 1 ,6 3,2
Magnesium stearate 2,2 4,4 8,8
200 400 800
Coating:
Polyethylene glycol (PEG) 0,832 1 ,331 2,162
8000
Cellulose HPM 603 4,595 7,352 11 ,947
Talcum 3,327 5,323 8,649
Titanium Dioxide 0,935 1 ,496 2,431
Iron oxide, yellow 0,312 0,499 0,81 10 16 26
Total 210 416 826
Mix the TRILEPTAL, cellulose HPM 603 (binder) and AVICEL PH 102 (binder, filler, disintegration-promoting excipient) in a mixer, preferably in a high-speed mixer (DIOSNA, LOEDIGE, FIELDER, GLATT etc.). Add water as granulation liquid to the mixture, and knead in a mixer, preferably a high-speed mixer, until an adequate consistency is achieved. Alternatively, the binder cellulose HPM may be dissolved in the granulation liquid, water, beforehand. Granulate the wet granules using a suitable device (ALEXANDER Reibschnitzler, QUADRO-COMILL) and dry in a fluidised bed (AEROMATIC, GLATT). Add AVICEL PH 102, AEROSIL 200 (flow conditioner) and polyvinylpyrrolidone PXL (disintegrator) to the dry granules and comminute and mix in a comminuter (FREWITT, QUADRO-COMILL, FITZMILL). Finally, add magnesium stearate (lubricant) and mix (STOECKLIN container mixer, VRIECO mixer). Alternatively, the lubricant may be added directly to the comminuted material. Compress the final mixture to form TRILEPTAL tablets (eccentric press, rotary press: KILIAN, KORSCH, FETTE, MANESTY).
Coat the tablets with an aqueous preparation consisting of cellulose HPM 603 (film former), iron oxide yellow 17268 (pigment), PEG 8000 (plasticiser for the film former), talcum (anti- adhesive agent, covering agent) and titanium dioxide (covering agent) in a rotating coating pan (ACCELA-COTA, GLATT, DRIACOATER, DUMOULIN). Alternatively, it is possible to use, for example, fluidised-bed or air-suspension apparatus for the coating process (AEROMATIC, GLATT, FREUND, HUETTLIN).
Example 2
(mg) (mg) (mg)
Tablet Core:
Oxcarbazepine 150,0 300,0 600,0
AvicelPH 102 28,8 57,5 115,0 Cellulose HPM 603 5,0 10,0 20,0
Nymcel ZSB IO 13,8 27,5 55,0
Aerosil 200 1 ,3 2,5 5,0
Magnesium Stearate 2,3 4,5 9,0
Total: 201,0 402,0 804,0
Coating:
Polyethylene glycol (PEG) 0,915 1 ,497 2,328
8000
Cellulose HPM 603 5,054 8,269 12,865
Talcum 3,659 5,988 9,314
Titanium dioxide 1 ,029 1 ,684 2,62
Iron oxide, yellow 0,343 0,561 0,873
11 18 28
Total 212,0 420,0 832,0
The oxacarbazepine, cellulose HPM 603 and Avicel PH 102 are mixed together in a planetary mixer (Aeschbach). Alcohol is added to this mixture before it is kneaded in a planetary mixer until a desired consistency is achieved. Thereafter the methodology according to Example 1 is followed to provide coated tablets.
Example 3
(mg) (mg) (mg)
Tablet Core:
Oxcarbazepine 150 300 600
Avicel PH 102 46 92 184
Cellulose HPM 603 6 12 24
Polyvinylpyrrolidone 10 20 40 Aerosil 200 0,8 1 ,6 3,2
Magnesium stearate 2,2 4,4 8,8
Total: 215 430 860
Coating:
Polyethylene glycol (PEG) 0,915 1 ,497 2,328
8000
Cellulose HPM 603 5,054 8,269 12,865
Talcum 3,659 5,988 9,314
Titanium Dioxide 1 ,029 1 ,684" 2,62
Iron oxide, yellow 0,343 0,561 0,873
11 18 28
Total 226 448 888
The same methodology as Example 1 is carried out on the formulation to provide coated tablets.

Claims

Claims
1. A formulation comprising oxacarbazepine having a median particle size of approximately 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m and with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2%.
2. A film-coated tablet comprising oxacarbazepine having a median particle size of approximately 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m and with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2%.
3. A film-coated tablet which comprises, a) a tablet core comprising a therapeutically effective dose of oxacarbazepine, preferably being in a finely ground form, having a median particle size of approximately from 4 to 12 ╬╝m, preferably 4 to 10 ╬╝m with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2 %, and further excipients that are suitable for the production of granules; and b) a hydrophilic permeable outer coating.
4 A film-coated tablet according to claim 3, which comprises a) a tablet core comprising a therapeutically effective dose of oxacarbazepine, preferably being in a finely ground form, having a median particle size of approximately from 6 to 8 ╬╝m with a maximum residue on a 40 ╬╝m sieve of 2 %, and further excipients that are suitable for the production of dry granules.
5 A film-coated tablet according to either claim 3 or claim 4, which comprises as component b) a hydrophilic permeable outer coating comprising white pigments, iron oxide pigment and optionally further excipients.
6. A process for the production of a film-coated tablet containing oxacarbazepine comprising forming the oxacarbazepine, having a median particle size of approximately from 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2 %, and optionally other excipients into a central core, and coating said core with a hydrophilic permeable outer coating.
7. A process for producing a film-coated tablet according to claim 3, which comprises finely grinding the oxacarbazepine to a median particle size of approximately from 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2 %, and, with the admixture of excipients that are suitable for granulation processes, forming the active ingredient into granules, compressing the granules to form tablet cores using conventional tabletting processes, and providing the cores with a hydrophilic permeable outer coating.
8 A process according to claim 7, which comprises forming the finely ground oxacarbazepine into wet granules with the admixture of excipients that are suitable for granulation processes, and compressing the wet granules to form tablet cores using conventional tabletting processes.
9. Oxacarbazepine having a median particle size of approximately 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m.
10. Oxacarbazepine having a median particle size of approximately 2 to 12╬╝m, preferably 4 to 12 ╬╝m, more preferably 4 to 10 ╬╝m and with a maximum residue on a 40 ╬╝m sieve of up to 5%, e.g. 2%.
PCT/EP1998/000794 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets WO1998035681A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SI9830485T SI0966287T1 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets
EP98908091A EP0966287B1 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets
BR9807368-0A BR9807368A (en) 1997-02-14 1998-02-12 Film-coated oxacarvazepine tablets
PL334959A PL193332B1 (en) 1997-02-14 1998-02-12 Film-coated oxacarbazepin tablets
SK1098-99A SK284503B6 (en) 1997-02-14 1998-02-12 The compositions containing oxacarbazepine, oxacarbazepine film-coated tablet and process for the production of said formulation and oxacarbazepine
DE69814367T DE69814367T2 (en) 1997-02-14 1998-02-12 OXACARBAZEPINE FILM-COVERED TABLETS
CA002277791A CA2277791C (en) 1997-02-14 1998-02-12 Oxcarbazepine film-coated tablets
IL13103998A IL131039A (en) 1997-02-14 1998-02-12 Formulation and film-coated tablet comprising oxacarbazepine and process for preparation thereof
AT98908091T ATE239481T1 (en) 1997-02-14 1998-02-12 FILM-COATED TABLETS OF OXACARBAZEPINE
AU66222/98A AU738030B2 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets
HU0000886A HU227807B1 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets, process for producing them
NZ336946A NZ336946A (en) 1997-02-14 1998-02-12 Oxacarbazepine (10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide) film-coated tablets with median particle size 2-12 um with a max residue of 40 um sieve of up to 5%
DK98908091T DK0966287T3 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets
JP10535347A JP2000511935A (en) 1997-02-14 1998-02-12 Oxcarbazepine film coated tablets
NO19993919A NO327486B1 (en) 1997-02-14 1999-08-13 Oxacarbazepine formulation, film-coated tablet and method of preparation thereof.
HK00103912A HK1024423A1 (en) 1997-02-14 2000-06-28 Oxacarbazepine film-coated tablets
US10/429,634 US7037525B2 (en) 1997-02-14 2003-05-05 Oxacarbazepine film-coated tablets
US11/582,802 US20070036863A1 (en) 1997-02-14 2006-10-18 Oxacarbazepine film-coated tablets
US11/879,329 US20080014269A1 (en) 1997-02-14 2007-07-17 Oxacarbazepine film-coated tablets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH331/97 1997-02-14
CH33197 1997-02-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09367361 A-371-Of-International 1999-08-11
US09/947,574 Continuation US20020022056A1 (en) 1997-02-14 2001-09-06 Oxacarbazepine film-coated tablets
US11/582,802 Continuation US20070036863A1 (en) 1997-02-14 2006-10-18 Oxacarbazepine film-coated tablets

Publications (1)

Publication Number Publication Date
WO1998035681A1 true WO1998035681A1 (en) 1998-08-20

Family

ID=4184588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000794 WO1998035681A1 (en) 1997-02-14 1998-02-12 Oxacarbazepine film-coated tablets

Country Status (32)

Country Link
US (2) US20070036863A1 (en)
EP (1) EP0966287B1 (en)
JP (3) JP2000511935A (en)
KR (3) KR19980071337A (en)
CN (2) CN1626093A (en)
AR (1) AR011142A1 (en)
AT (1) ATE239481T1 (en)
AU (1) AU738030B2 (en)
BR (1) BR9807368A (en)
CA (1) CA2277791C (en)
CO (1) CO4920215A1 (en)
CY (1) CY2480B1 (en)
CZ (1) CZ298840B6 (en)
DE (1) DE69814367T2 (en)
DK (1) DK0966287T3 (en)
ES (1) ES2199422T3 (en)
HK (1) HK1024423A1 (en)
HU (1) HU227807B1 (en)
ID (1) ID22348A (en)
MY (1) MY117582A (en)
NO (1) NO327486B1 (en)
NZ (1) NZ336946A (en)
PE (1) PE58999A1 (en)
PL (1) PL193332B1 (en)
PT (1) PT966287E (en)
RU (1) RU2201218C2 (en)
SK (1) SK284503B6 (en)
TR (1) TR199901804T2 (en)
TW (1) TW529957B (en)
UY (1) UY24888A1 (en)
WO (1) WO1998035681A1 (en)
ZA (1) ZA981205B (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1157690A1 (en) * 2000-05-26 2001-11-28 Pharma Pass LLC Sustained release pharmaceutical composition
WO2004026314A1 (en) * 2002-09-20 2004-04-01 Novartis Ag Modified release formulations of oxcarbazepine and derivatives thereof
WO2005020968A2 (en) 2003-09-03 2005-03-10 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
WO2005092294A1 (en) * 2004-03-22 2005-10-06 Novartis Ag Oral matrix formulations comprising licarbazepine
WO2005092290A1 (en) * 2004-03-22 2005-10-06 Novartis Ag Disintegrating tablets comprising licarbazepine
US7070811B2 (en) 2001-12-21 2006-07-04 Pfizer Inc. Directly compressible formulations of azithromycin
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
JP2007224041A (en) * 1999-11-02 2007-09-06 Novartis Ag Pharmacological composition
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
EP1929997A1 (en) * 2006-12-08 2008-06-11 Sun Pharmaceutical Industries LTD Oxcarbazepine formulations
WO2008074097A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
EP1951197A1 (en) * 2005-11-10 2008-08-06 Alphapharm Pty Ltd. Process to control particle size
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
EP2010499A1 (en) * 2006-04-21 2009-01-07 Alphapharm Pty Ltd. Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
US8367106B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
US8852634B2 (en) 2005-09-23 2014-10-07 Hoffmann-La Roche Inc. Dosage formulation
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
US10597384B2 (en) 2007-12-07 2020-03-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10675287B2 (en) 2005-05-06 2020-06-09 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US11052075B2 (en) 2010-04-07 2021-07-06 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (en) * 1997-02-14 2000-05-29 Novartis Ag OXACARBAZEPINE TABLETS COATED WITH A FILM AND METHOD FOR THE PRODUCTION OF THESE FORMULATIONS
MX2008013675A (en) * 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile.
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
CN103735527B (en) * 2013-12-24 2014-09-10 武汉人福药业有限责任公司 Oxcarbazepine tablets and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409212A (en) * 1981-04-16 1983-10-11 Ciba-Geigy Corporation Method of preventing and treating cerebral insufficiency
WO1994013298A1 (en) * 1992-12-16 1994-06-23 Rhone-Poulenc Rorer S.A. Application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries
WO1994020110A1 (en) * 1993-03-05 1994-09-15 Rhone-Poulenc Rorer S.A. Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders
EP0646374A1 (en) * 1993-09-08 1995-04-05 Ciba-Geigy Ag Double-coated oxcarbazepine containing tablets
WO1995029665A1 (en) * 1994-04-28 1995-11-09 Alza Corporation Effective dosage form for antiepileptic drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75561C (en) * 1979-10-30 1988-07-11 Ciba Geigy Ag Process for the preparation of 5-carbamoyl-10-oxo-10,11-dihydro-5H-di benz / b, f / azepine and necessary intermediates thereto.
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
JPS6257467A (en) * 1985-09-06 1987-03-13 Asahi Glass Co Ltd Coating agent composition
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
CH668187A5 (en) * 1986-08-07 1988-12-15 Ciba Geigy Ag THERAPEUTIC SYSTEM WITH SYSTEMIC EFFECT.
DD295760A5 (en) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De DRUG DISTRIBUTION SYSTEM WITH COTROLLED ACTIVE INGREDIENT TRANSFER
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
US5478654A (en) * 1994-05-06 1995-12-26 Gencorp Inc. Solventless carboxylated butadiene-vinylidene chloride adhesives for bonding rubber to metal
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (en) * 1997-02-14 2000-05-29 Novartis Ag OXACARBAZEPINE TABLETS COATED WITH A FILM AND METHOD FOR THE PRODUCTION OF THESE FORMULATIONS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4409212A (en) * 1981-04-16 1983-10-11 Ciba-Geigy Corporation Method of preventing and treating cerebral insufficiency
WO1994013298A1 (en) * 1992-12-16 1994-06-23 Rhone-Poulenc Rorer S.A. Application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries
WO1994020110A1 (en) * 1993-03-05 1994-09-15 Rhone-Poulenc Rorer S.A. Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders
EP0646374A1 (en) * 1993-09-08 1995-04-05 Ciba-Geigy Ag Double-coated oxcarbazepine containing tablets
WO1995029665A1 (en) * 1994-04-28 1995-11-09 Alza Corporation Effective dosage form for antiepileptic drugs

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007224041A (en) * 1999-11-02 2007-09-06 Novartis Ag Pharmacological composition
CZ302847B6 (en) * 1999-11-02 2011-12-14 Novartis Ag Oral dosage forms containing oxcarbazepine
JP2012211202A (en) * 1999-11-02 2012-11-01 Novartis Ag Pharmaceutical composition
EP1157690A1 (en) * 2000-05-26 2001-11-28 Pharma Pass LLC Sustained release pharmaceutical composition
EP1690530A2 (en) * 2000-05-26 2006-08-16 Pharma Pass LLC Sustained release pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
EP1690530A3 (en) * 2000-05-26 2007-07-18 Biovail Laboratories International Srl Sustained release pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
US7070811B2 (en) 2001-12-21 2006-07-04 Pfizer Inc. Directly compressible formulations of azithromycin
WO2004026314A1 (en) * 2002-09-20 2004-04-01 Novartis Ag Modified release formulations of oxcarbazepine and derivatives thereof
WO2005020968A2 (en) 2003-09-03 2005-03-10 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
US10626111B2 (en) 2004-01-30 2020-04-21 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005092290A1 (en) * 2004-03-22 2005-10-06 Novartis Ag Disintegrating tablets comprising licarbazepine
AU2005226910B2 (en) * 2004-03-22 2009-06-04 Novartis Ag Oral matrix formulations comprising licarbazepine
WO2005092294A1 (en) * 2004-03-22 2005-10-06 Novartis Ag Oral matrix formulations comprising licarbazepine
US8597666B2 (en) 2004-11-10 2013-12-03 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367106B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US10702536B2 (en) 2005-05-06 2020-07-07 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US10675287B2 (en) 2005-05-06 2020-06-09 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US10695354B2 (en) 2005-05-06 2020-06-30 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US11364247B2 (en) 2005-05-06 2022-06-21 Bial-Portela & Ca S.A. Methods of treatment of partial onset seizures using eslicarbazepine acetate
US8852634B2 (en) 2005-09-23 2014-10-07 Hoffmann-La Roche Inc. Dosage formulation
US11084804B2 (en) 2005-11-08 2021-08-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd Process to control particle size
AU2006313009B2 (en) * 2005-11-10 2013-10-24 Alphapharm Pty Ltd Process to control particle size
US9034381B2 (en) 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
EP1951197A1 (en) * 2005-11-10 2008-08-06 Alphapharm Pty Ltd. Process to control particle size
WO2007089926A3 (en) * 2006-01-31 2008-12-24 Teva Pharma Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP1815849A1 (en) * 2006-01-31 2007-08-08 Teva Pharmaceutical Industries Ltd Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007089926A2 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2010499A4 (en) * 2006-04-21 2012-07-18 Alphapharm Pty Ltd Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
EP2010499A1 (en) * 2006-04-21 2009-01-07 Alphapharm Pty Ltd. Pharmaceutical compositions of oxcarbazepine with a median particle size of 15 to 30 microns
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
EP1929997A1 (en) * 2006-12-08 2008-06-11 Sun Pharmaceutical Industries LTD Oxcarbazepine formulations
EP2476418A1 (en) 2006-12-21 2012-07-18 Alphapharm Pty Ltd. Pharmaceutical compound and composition for use in treating type II diabetes comprising rosiglitazone in a specific particle size
WO2008074097A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
WO2008141751A2 (en) * 2007-05-23 2008-11-27 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
WO2008141751A3 (en) * 2007-05-23 2009-07-16 Ratiopharm Gmbh Pharmaceutical compositions comprising oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US10912781B2 (en) 2007-10-26 2021-02-09 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US9566244B2 (en) 2007-10-26 2017-02-14 Bial-Portele & Ca, S.A. Pharmaceutical composition comprising licarbazepine acetate
US10597384B2 (en) 2007-12-07 2020-03-24 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US11052075B2 (en) 2010-04-07 2021-07-06 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability

Also Published As

Publication number Publication date
BR9807368A (en) 2000-03-14
CN1626093A (en) 2005-06-15
JP2006077029A (en) 2006-03-23
TR199901804T2 (en) 1999-09-21
ES2199422T3 (en) 2004-02-16
PL193332B1 (en) 2007-02-28
AR011142A1 (en) 2000-08-02
HUP0000886A3 (en) 2002-10-28
DE69814367D1 (en) 2003-06-12
ATE239481T1 (en) 2003-05-15
KR20120079826A (en) 2012-07-13
HU227807B1 (en) 2012-03-28
DK0966287T3 (en) 2003-08-25
CZ287999A3 (en) 1999-11-17
KR20090037873A (en) 2009-04-16
US20080014269A1 (en) 2008-01-17
CA2277791C (en) 2008-11-18
AU738030B2 (en) 2001-09-06
PE58999A1 (en) 1999-06-25
DE69814367T2 (en) 2004-02-26
RU2201218C2 (en) 2003-03-27
TW529957B (en) 2003-05-01
MY117582A (en) 2004-07-31
CY2480B1 (en) 2005-06-03
JP2000511935A (en) 2000-09-12
PL334959A1 (en) 2000-03-27
ID22348A (en) 1999-09-30
EP0966287A1 (en) 1999-12-29
SK284503B6 (en) 2005-05-05
NO993919D0 (en) 1999-08-13
HK1024423A1 (en) 2000-10-13
UY24888A1 (en) 2000-12-29
NO327486B1 (en) 2009-07-13
KR19980071337A (en) 1998-10-26
SK109899A3 (en) 2000-03-13
NZ336946A (en) 2001-02-23
ZA981205B (en) 1998-08-14
US20070036863A1 (en) 2007-02-15
CN1170542C (en) 2004-10-13
CZ298840B6 (en) 2008-02-20
HUP0000886A2 (en) 2000-09-28
CN1247471A (en) 2000-03-15
AU6622298A (en) 1998-09-08
NO993919L (en) 1999-08-13
PT966287E (en) 2003-09-30
CA2277791A1 (en) 1998-08-20
JP2010132694A (en) 2010-06-17
CO4920215A1 (en) 2000-05-29
EP0966287B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
EP0966287B1 (en) Oxacarbazepine film-coated tablets
US7037525B2 (en) Oxacarbazepine film-coated tablets
AU777705B2 (en) Pharmaceutical compositions
CA2131495C (en) Double-layered oxcarbazepine tablets
WO2009026621A1 (en) Pharmaceutical compound & composition
NZ509391A (en) Oxacarbazepine film-coated tablets further comprising a hydrophobic permeable outer coating containing iron oxide from 0.3 to 0.9 mg per tablet
MXPA99007514A (en) Oxacarbazepine film-coated tablets

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131039

Country of ref document: IL

Ref document number: 98802497.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 66222/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998908091

Country of ref document: EP

Ref document number: 1199900549

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2277791

Country of ref document: CA

Ref document number: 2277791

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 336946

Country of ref document: NZ

Ref document number: 1999/01804

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09367361

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 109899

Country of ref document: SK

Ref document number: PV1999-2879

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 535347

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/007514

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: PV1999-2879

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998908091

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 66222/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998908091

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2004-749

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1999-2879

Country of ref document: CZ